Please login to the form below

Not currently logged in
Email:
Password:

Valeant acquires Swiss pharma company

Canada's Valeant Pharmaceuticals has signed a deal to acquire Swiss firm PharmaSwiss S.A. for €350m in a move to strengthen its European presence

Canada's Valeant Pharmaceuticals International has signed a deal to acquire the privately held Swiss firm PharmaSwiss S.A. for €350m in a move to strengthen its European presence.

PharmaSwiss, which specialises in branded generics and over-the-counter (OTC) drugs, is based in Zug, Switzerland, and has operations in 19 countries throughout Central and Eastern Europe, including Poland, Hungary, the Czech Republic and Serbia. The company had revenues of about €180m in 2010 and has been growing at an annual rate of about 20 per cent over the past five years.

PharmaSwiss' senior management team will remain in place after the closing of the acquisition, working closely with the Valeant Europe team. Eventually, Valeant plans to fold its business in Central Europe into the PharmaSwiss corporate structure.

Valeant expects operating income as a percentage of revenue of the combined Central and Eastern European business to be similar to that of Valeant's historical branded generic European business.

The deal is expected to close before the end of the second quarter of 2011 and to be immediately accretive to Valeant. 

Valeant said it was attracted to the Swiss firm because of its active partnering strategy and complementary branded generics and OTC product portfolio. PharmaSwiss has partnerships with multinational companies including Amgen, Astellas, Bristol-Myers Squibb, Ferring, Ipsen, Lilly, Norgine, and Pfizer.

Valeant develops and markets pharmaceuticals with a focus on neurology, dermatology and branded generics. The company as it currently exists was created last year when the Canadian pharma company Biovail acquired the US-based company called Valeant, creating the merged company that now operates under the name.

2nd February 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...
Reframing rare to increase earlier diagnosis of Gaucher Disease
Sanofi Genzyme wanted to reach haematologists; the specialist physicians most likely to encounter patients with Gaucher Disease prior to diagnosis. The problem? Gaucher Disease is considered very rare and its...